Mayo Clinic Maps 'Zombie' Cells, Finds New Aging Therapy Paths — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Mayo Clinic scientists published seven studies identifying how 'zombie' cells vary by tissue and origin, developing the SenMayo gene set to detect them more reliably across experimental systems
- SenMayo gene set was validated using bone biopsies from older adults and showed reduced activity after senescent cell removal, becoming a widely adopted tool in aging research
- Mitochondrial dysfunction in senescent cells drives chronic inflammation through leaked mitochondrial RNA and metabolic-epigenetic crosstalk, offering new treatment pathways beyond cell elimination
- Natural compound in tomatoes, along with senolytic drugs and genetic techniques, reduced inflammation and improved physical and cognitive function in aging mice in preclinical trials
- IL-23R was identified as a potential blood-based biomarker of biological aging, which could help measure the effectiveness of future anti-aging therapies
- Cellular Senescence Network (SenNet) Consortium receives NIH funding to map senescent cells across human tissues, with Mayo Clinic contributing foundational tools and data
Why it matters: These findings shift the focus from broadly eliminating zombie cells to precisely targeting their harmful mechanisms, which could accelerate the development of therapies that delay or prevent multiple age-related diseases. For pharmaceutical developers and aging researchers, this creates a clearer path to clinical interventions with measurable biomarkers like IL-23R.
Ask SkimNews
